Quantcast
Last updated on April 24, 2014 at 0:07 EDT

Latest Ramucirumab Stories

2014-04-21 20:21:44

INDIANAPOLIS, April 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA(TM) (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this approval, CYRAMZA becomes the first FDA-approved treatment for patients...

2014-04-03 12:30:00

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth SummaryGBI Research has released the pharma report "Monoclonal...

2014-02-21 08:26:00

DALLAS, February 21, 2014 /PRNewswire/ -- RnRMarketResearch.com offers cancer monoclonal antibodies market (mABs) research reports covering pipeline analysis as well as monoclonal antibodies market forecasts in breast cancer, colorectal cancer as well as gastric and esophageal cancers to 2019. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient's lifespan; Avastin, Erbitux and...

2013-12-14 23:00:56

MarketResearchReports.Biz announces addition of new report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth. Albany, NY (PRWEB) December 14, 2013...

2013-10-03 09:31:58

The phase III study published in the The Lancet shows that an antibody (ramucirumab) inhibits the action of various proteins involved in tumor growth, prolonging survival of patients with advanced gastric cancer This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer. Standard care for advanced gastric cancer, known as first-line treatment, is based on chemotherapy, but it only offers a median survival of 8 to 10...

2012-10-15 07:28:52

INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab. The REGARD trial compared ramucirumab and best supportive care to placebo and best supportive care as a second-line...

2012-09-05 23:04:23

New research study “Gastric Cancer - Brazil, Russia, India and China (BRIC) Drug Forecasts and Treatment Analysis to 2020” prepared by GlobalData has been recently published by Market Publishers Ltd. The report finds that the global gastric cancer drug market will experience robust growth over the next decade. London, UK (PRWEB) September 04, 2012 The global gastric cancer drug market will experience robust growth over the next decade, driven by the rapid uptake and market...

2012-03-29 21:48:03

Max Planck researchers unravel a critical regulatory mechanism controlling blood vessel growth that might help solve drug resistance problems in the future Angiogenesis, the growth of new blood vessels, is a complex process during which different signalling proteins interact with each other in a highly coordinated fashion. The growth factor VEGF and the Notch signalling pathway both play important roles in this process. VEGF promotes vessel growth by binding to its receptor, VEGFR2, while...

2009-07-22 08:00:00

TUSTIN, Calif. and HORSHOLM, Denmark, July 22 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) and Affitech A/S (Nasdaq OMX: AFFI) today announced that they have entered into a licensing agreement for antibody therapeutic rights under Peregrine's preclinical anti-VEGF (Vascular Endothelial Growth Factor) antibody program. Under the terms of the agreement, Affitech will license exclusive worldwide rights to develop and commercialize products under Peregrine's...

2009-04-22 09:00:00

-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform- -Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%- DENVER and TUSTIN, Calif., April 22 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer...